Objective To compare the clinical features and the total duration of endocrine therapy between immunohistochemical hormone receptor positive and human epidermal growth factor negative groups (HR+/HER2-) and hormone receptor positive and human epidermal growth factor receptor positive groups (HR+/HER2+).Methods The clinical features of 58 cases of breast cancer treated in the Affiliated Hospital of Qingdao University were analyzed retrospectively, including 36 cases of HR+/HER2- and 22 cases of HR+/HER2+. The age, menstrual status, bone metastasis, lung metastasis, liver metastasis, lymph node metastasis, total number of metastases, BMI, BI-RADS grade, ECOG score and total endocrine therapy duration, first-line endocrine therapy duration, second-line endocrine therapy duration, third-line and above endocrine therapy duration were compared between the two groups.Results There were no statistical differences between the two groups in age, menstrual status, lung metastasis, liver metastasis, lymph node metastasis, total metastasis, BMI, BI-RADS grade, ECOG score, total endocrine therapy duration, first-line endocrine therapy duration and second-line endocrine therapy duration (P>0.05). The incidence of bone metastasis in HR+/HER2+ group was higher than that in HR+/HER2- group, and the duration of third-line and above endocrine therapy in HR+/HER2- group was longer than that in HR+/HER2+ group, with statistical significance (P<0.05).Conclusion HR+/HER2+ breast cancer can be actively treated with endocrine therapy or in combination with HER2-targeted drugs, so as to avoid the use of chemotherapy and reduce the adverse reactions caused by chemotherapy.